Holen Sie sich die Stockscreener-App
12.45
1.09%
-0.175
Schlusskurs vom Vortag:
$12.62
Offen:
$12.5
24-Stunden-Volumen:
166.56K
Relative Volume:
0.11
Marktkapitalisierung:
$1.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-135.21M
KGV:
-8.6961
EPS:
-1.4311
Netto-Cashflow:
$-114.35M
1W Leistung:
-4.93%
1M Leistung:
-7.54%
6M Leistung:
+7.14%
1J Leistung:
+14.41%
1-Tages-Spanne:
$12.41
$12.89
1-Wochen-Bereich:
$12.43
$13.41
52-Wochen-Spanne:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.41 | 1.31B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
523.00 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.20 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.04 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.94 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.37 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-12 | Fortgesetzt | Stifel | Buy |
| 2026-05-15 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - Kalkine
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - AD HOC NEWS
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - AD HOC NEWS
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - MarketBeat
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) Slips 1.17% as Biotech Stock Approaches Key Support at $12.89Vanna Flow - dars.gov.et
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - MarketBeat
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27 - Moomoo
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 60% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC? - Sahm
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25 - Moomoo
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% HigherHere's What Happened - MarketBeat
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals (ORIC) Projected to Release Earnings on Tuesday - MarketBeat
ORIC SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
ORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signals - GuruFocus
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary - TradingView
ORIC: Net loss rose to $77.3M as R&D spending increased; cash runway extends into H2 2028 - TradingView
ORIC: Advanced late-stage oncology pipeline with strong cash position and key trials underway - TradingView
Oric Pharmaceuticals reports Q2 2026 net loss $41.5M, cash $387.6M; Phase 3 trial initiated - TradingView
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2%Should You Sell? - MarketBeat
ORIC Pharmaceuticals starts Phase 3 trial for p... - Pluang
Avoiding Lag: Real-Time Signals in (ORIC) Movement - Stock Traders Daily
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan - The Globe and Mail
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 77.77% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Aug 26 '26 |
Sale |
13.69 |
77,000 |
1,053,814 |
69,828 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):